Search Within

David J Straus

Formats
  1. Meeting Abstract (168)
  2. Journal Article (166)
  3. Book Section (15)
  4. Conference Paper (5)
  5. Research Letter (3)
  6. Editorial (2)
  7. Correspondence (1)
  8. Review (1)
Groups
  1. Center for Hematologic Malignancies (361)
  2. Department of Medicine (361)
  3. Hematologic Malignancies, Division of (361)
  4. Lymphoma (361)
  5. Survivorship Research (162)
  6. Population Sciences Research Program (129)

More Groups

People
  1. Andrew Zelenetz (163)
  2. Ariela Noy (139)
  3. Paul Hamlin (122)
  4. Steven Horwitz (122)
  5. Craig Moskowitz (117)
  6. Matthew Matasar (104)

More People

Years
  1. 2024 (10)
  2. 2023 (9)
  3. 2022 (13)
  4. 2021 (27)
  5. 2020 (25)
  6. 2019 (21)

More Years

Publications
  1. Blood (117)
  2. Journal of Clinical Oncology (44)
  3. Hematological Oncology (19)
  4. Cancer (14)
  5. Leukemia and Lymphoma (13)
  6. British Journal of Haematology (11)

More Publications

Publishers
  1. American Society of Hematology (124)
  2. American Society of Clinical Oncology (46)
  3. Wiley Blackwell (36)
  4. Elsevier Inc. (23)
  5. Taylor & Francis Group (14)
  6. John Wiley & Sons (12)

More Publishers

Results (361)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: Interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C)
    Meeting Abstract

    Lee, H. J.; Abramson, J. S.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Eva, D. D.; Hess, B. T.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
    Meeting Abstract

    Ansell, S. M.; Connors, J. M.; Radford, J. A.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R. H.; Hutchings, M.; Evens, A. M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin in advanced Hodgkin's lymphoma: The authors reply
    Correspondence

    Ansell, S. M.; Radford, J.; Straus, D. J.
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma
    Journal Article

    Ansell, S. M.; Radford, J.; Connors, J. M.; Długosz-Danecka, M.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R.; Hutchings, M.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Research Letter

    Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
    Cancer Cell (2022)

    Fulltext@MSK | Save